February 21, 2017
CureDuchenne Applauds the FDA Approval of Marathon’s EMFLAZA (deflazacort) for the Treatment...
Read More
January 23, 2017
CureDuchenne Creates New Program to Improve PT Training and Clinical Trial Education
Read More
January 19, 2017
Why Health Insurers Won't Cover this $300,000-a-year Rare Disease Drug
Read More
December 1, 2016
CureDuchenne Aims for a Treatment for the 87%
Read More
November 11, 2016
RARECast: Discovering the Creative Use of Outrage
Read More
October 9, 2016
CureDuchenne Cares Hosts Inaugural Family Summit This October
Read More
September 30, 2016
RARECast: A Controversial Approval for a Duchenne Drug and What Lies Ahead
Read More
August 11, 2016
Early Stage Investment by CureDuchenne Ventures, LLC Enabled Bamboo Therapeutics to Accelerate...
Read More
July 25, 2016
Clinical Trial Gave Me Quality of Life: A Continued Fight for the DMD…
Read More
June 30, 2016
Marathon Pharmaceuticals Announces Submission of Deflazacort New Drug Application to the FDA
Read More
May 9, 2016
Marathon Pharmaceuticals Presents Analyses at AAN of a Phase III Clinical Study of…
Read More
April 30, 2016
Introducing the Path To Hope Campaign in Response to FDA Decision on Eteplirsen
Read More
Load More